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The primer binding site (PBS) plays pivotal roles during reverse transcription of retroviruses and also is the target of a
cellular host defense impeding the transcription of murine leukemia virus (MLV) harboring a proline (pro) PBS in embryonic
cells. Both the PBS and the tRNA primer are copied during reverse transcription and anneal as complementary DNA
sequences creating the PBS of the integrated provirus. The pro PBS of MLV can be exchanged by PBS sequences matching
endogenous or engineered tRNAs to allow replication of Akv MLV-derived vectors in fibroblasts. Here we use the PBS escape
mutant B2 to demonstrate the capacity of the synthetic tRNAB2 to function in reverse transcription in competition with
endogenous tRNAs in fibroblasts and embryonic carcinoma (EC) cells. We further show symmetry between PBS and the
primer by the ability of the synthetic tRNAB2 to confer escape from EC repression of a PBS-Pro vector. Of a panel of vectors
with the repressed pro PBS substituted for other natural or artificial PBS sequences, all except one efficiently expressed the
neo marker gene when transferred to NIH/3T3 and EC cells, hence avoiding PBS-mediated silencing in EC cells. A
non-natural PBS matching an artificially designed tRNA molecule conferred no further relief from repression than that
attained with the B2 escape mutant or the natural alternative PBSs. Interestingly, a vector harboring a PBS matching tRNALys1.2
suffered repression similar to the wild-type PBS-Pro but was partially rescued by a single point mutation of the PBS. © 2000
Academic Press
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To copy the single-stranded RNA genome of retrovi-
ruses into a double-stranded DNA provirus, the cellular
tRNA copackaged in the virion serves as primer for
reverse transcriptase by annealing of its 39 18 nucleo-
ides to the complementary PBS near the 59 end of the
viral genome (Gilboa et al., 1979). During minus-strand
synthesis, the PBS present in the RNA genome is copied
into DNA, whereas the corresponding sequence of the
tRNA is copied during synthesis of the plus strand. An-
nealing of the complementary sequences then mediates
the second template switch of reverse transcription and
generates the PBS of the transduced provirus (Gilboa et
al., 1979). Different tRNAs are used by different viruses.
Murine leukemia virus (MLV) (Peters et al., 1977) and
human T-cell leukemia virus (Seiki et al., 1983) replicate
via tRNAPro, mouse mammary tumor virus, and human
immunodeficiency virus via tRNALys3 (Majors and Varmus,
983; Wain-Hobson et al., 1985); visna, spuma, and Ma-
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368on-Pfizer monkey viruses use tRNALys1.2 (Sonigo et al.,
1985, 1986; Maurer et al., 1988); and avian retroviruses
use tRNATrp (Sawyer and Dahlberg, 1973). The PBS of
ome endogenous murine proviruses match tRNAGln (Ou
t al., 1983; Nikbakht et al., 1985), and a PBS comple-
entary to tRNAPhe is found in mouse and hamster intra-
isternal A particles (Cohen et al., 1983; Ono and Ohishi,
983). For a given virus, the PBS element, and thus the
nteracting tRNA, is highly conserved, yet replication of
LV and MLV-derived vectors is compatible with several
BS-tRNA combinations in cell cultures (Colicelli and
off, 1987; Lund et al., 1993, 1997, 2000a) and in mice
Lund et al., 1999). tRNAGln was found to support trans-
duction of Moloney MLV (MoMLV) revertant dl587rev
(Colicelli and Goff, 1987), and we have previously shown
PBS-mutated retroviral vectors derived from Akv-MLV to
replicate efficiently using tRNAGln1,2, tRNALys3 (Lund et al.,
1993), tRNASer, tRNAArg, tRNAPhe (Lund et al., 2000a), and
genetically engineered tRNA molecule (Lund et al.,
997).
The developmental restraints on such a pivotal ele-
ent make it a candidate target for cellular mechanisms
alancing virus–host interactions. Hence the PBS of MLV
hat matches tRNAPro has been found to coincide with a
negatively acting cis-element mediating transcriptional
silencing of MoMLV and MoMLV-based vector provi-
ruses in embryonic carcinoma (EC) cells (Teich et al.,
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369MLV EXPRESSION IN EC CELLS BY PRIMERS AND PBSs1977; D’Auriol et al., 1981; Stewart et al., 1982; Weiher et
al., 1987) and embryonic stem (ES) cells (Grez et al.,
990; Kempler et al., 1993) and in cells of the early
mbryo (Ja¨hner et al., 1982; Vernet and Cebrian, 1996). A
ingle base pair change from G to A at position 15 of
oMLV PBS was identified in a search of escape mu-
ants in EC cells and found to be sufficient for relief of a
ector from repression (Barklis et al., 1986). In accor-
dance with this, the PBS of the MoMLV revertant
dl587rev with multiple base pair differences changing it
to match a tRNAGln (Colicelli and Goff, 1987) is compatible
ith expression in ES cells (Grez et al., 1990). The si-
encer activity of the PBS region has by several criteria
een separated from its roles during reverse transcrip-
ion; hence repression is seen both in transfection as-
ays independent of the presence of retroviral proteins
Barklis et al., 1986; Loh et al., 1987, 1988, 1990; Feuer et
al., 1989), with the element in either orientation, and
when placed in an intron (Petersen et al., 1991) or outside
of the transcriptional unit (Loh et al., 1990). Detailed
mapping studies have delimited the negative element to
a region overlapping the PBS, and only very few alter-
ations of the sequence retain silencer functions (Loh et
al., 1990; Petersen et al., 1991; Kempler et al., 1993).
Graduated but variable levels of repression were attrib-
uted to various PBS sequences in a study of MoMLV-
derived vectors with test sequences inserted down-
stream of a gln PBS (Yamauchi et al., 1995), suggesting
that some PBS sequences might escape repression only
partially. Whether the singly mutated B2 PBS or the other
tRNA-matching PBSs of similar activity are completely
devoid of repressive effects or alternative non-tRNA-
matching sequences might exist that would confer fur-
ther escape from repression by the PBS silencer is not
known. From in vitro studies of factor binding to PBS
sequences, repression has been suggested to be medi-
ated by a cellular protein, factor A (Yamauchi et al., 1995).
Because factor A was also detected in permissive fibro-
blasts (Petersen et al., 1991), however, the identity of host
cellular factors involved and their mode of operation in
PBS silencer-mediated repression remain unclear.
In this study, we investigated repression in F9 cells
using the ability of MLV to replicate via various PBS-tRNA
sets. Several natural and engineered PBS-tRNA comple-
ments are tested for repression in the context of their
reverse transcription function by replacing pro wild-type
(wt) PBS at the homologous position in Akv MLV-derived
vectors. An engineered tRNAB2 primer encoding the B2
BS mutation is used to discern participation of the
ngineered molecule in competition with endogenous
RNAs and to show symmetry during reverse transcrip-
ion between the primer and the PBS in providing relief
rom repression in F9 cells. Alleviation of repression is
onferred by all of the variant PBS sequences tested
xcept lys1.2 PBS. A partial escape mutant containing a
ingle base substitution compared with lys1.2 PBS isnferred from primer extension analysis of expressed
roviruses.
RESULTS
eplication with a synthetic tRNA primer on a
ackground of matching endogenous tRNAs
Replication of Akv MLV-derived vectors with a muta-
ionally impaired PBS can be restored by an engineered
omplementary tRNA primer, functional in both the initi-
tion of first-strand synthesis and second-strand transfer
Lund et al., 1997). We were interested in the ability of
ynthetic tRNA primers to complement vectors harboring
functional PBS on a background of competing endog-
nous tRNAs. The Akv MLV-derived vectors PBS-Pro
Lund et al., 1993) and PBS-B2 (Fig. 1A) harboring the
TR-promoted G418-selectable neo gene differ in the
5th position of the PBS sequence by a G-to-A mutation
resent in the B2 PBS (Barklis et al., 1986). This mutation
ives a single base difference from perfect complemen-
arity to a tRNAPro primer and can be used to determine
se of a synthetic tRNA molecule in reverse transcrip-
ion. We incorporated the B2 mutation into either the PBS
f the vector or an engineered tRNA molecule, tRNAB2
(Figs. 1A–1C), constructed from oligodeoxynucleotides to
resemble the backbone of the gene for tRNAPro. The
09-bp synthetic minigene encoding the tRNA includes
7 bp upstream and 10 bp downstream of the mature
RNA gene and holds intragenic promoter regions, the A
nd B box, for RNA polymerase III transcription (Sprague,
995). We have previously shown a similarly sized syn-
hetic tRNAx2 gene (Fig. 1B) to be proficiently expressed
o complement the replication deficiency of a PBS mu-
ated vector in transduced fibroblasts (Lund et al., 1997).
o control for possible adverse effects of adding syn-
hetic tRNAs, a plasmid encoding a putative full-length
RNAPro, including larger regions upstream and down-
stream of the mature tRNA molecule that might contrib-
ute to expression (Pavesi et al., 1994), was constructed
by PCR amplification of 446 bp from the murine Pro-tRNA
gene (Russo et al., 1986). Vector constructs and artificial
tRNAs were cotransfected into the BOSC 23 packaging
cell line (Pear et al., 1993), and transduction titers were
determined by transfer of transiently produced virus par-
ticles to NIH/3T3 cells followed by G418 selection (Fig. 2).
The PBS of a transduced provirus derives from a
DNA copy of the PBS sequence in the original vector
annealing to a DNA copy of the 18 39 nucleotides in the
tRNA primer during reverse transcription. A marker
mutation hence results in a mismatched PBS after
second-strand transfer, which may be corrected by
cellular repair systems according to either template or,
if cell division occurs before repair, lead to two differ-
ent proviruses integrated at identical locations in the
cellular genome (Berwin and Barklis, 1993). In any
case, a mutant might revert at high frequency (Barklis
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370 MODIN ET AL.et al., 1986; Rhim et al., 1991), providing genetic evi-
dence for use of a specific tRNA primer in reverse
transcription (Berwin and Barklis, 1993; Lund et al.,
1993 and 1997). The transduced PBS sequences were
analyzed by primer extension dideoxy termination on
genomic DNA from G418-selected cell populations. In
this analysis, the presence of pro and B2 PBS provi-
ruses can be distinguished in terms of a 24-mer pro
and a 22-mer B2 band arising from termination at the
first encountered T in the template by incorporation of
a dideoxy nucleotide analog (Fig. 2). Regardless of
cotransfected synthetic tRNAs, PBS-Pro and PBS-B2
transduce NIH/3T3 fibroblasts with similar efficiencies
in parallel experiments, ranging from 1.3 3 104 to 6.3 3
05 cfu/ml (Table 1). PBS-B2, regardless of cotransfec-
tion of tRNAPro, gives rise to a population of cells
FIG. 1. Structure of vectors and engineered tRNA primers. (A) Vector
the 3.4-kb vector PBS-Pro was replaced with modified PBS sequence
(PBS-Gln), lys3 (PBS-Lys3), phe [PBS-Phe, PBS-Phe(m)], or lys1.2 [PBS-L
differentiating PBS-B2 and PBS-x2 from PBS-Pro, PBS-Phe(m) from P
selectable neo gene is expressed from the LTR. Striped boxes indicate l
transcription of the vector. (B) Sequences of engineered tRNA molecu
Pro-tRNA gene (Russo et al., 1986) encompassed in the synthetic minig
997) relative to the Pro-tRNA gene are indicated. Elements important f
BS are underlined. Linkers for cloning of the minigenes are not includ
et al., 1979). Nucleotides mutated in tRNAx2 (shaded) and tRNAB2 (arrocontaining equal amounts of B2 and pro PBS provi-
ruses as predicted from reversion to wt during reverse
o
mtranscription (Barklis et al., 1986) (Fig. 2, left, lanes 2
nd 3). The engineered tRNA molecule per se hence
oes not appear to adversely affect the transduction,
et no evidence concerning participation of the mole-
ule in transfer is obtained. However, when providing
he B2 mutation in the artificial tRNA, specific use of
he engineered molecule in reverse transcription is
emonstrated. Accordingly, the distribution is shifted
oward B2 PBS proviruses when tRNAB2 is combined
with a PBS-B2 vector (Fig. 2, lane 4), or tRNAB2 gives
ise to detectable levels of B2 PBS proviruses when in
onjunction with PBS-Pro (Fig. 2, lane 5) as opposed to
he pure population obtained with PBS-Pro alone (Fig.
, lane 1). Thus the amount of artificial tRNA molecules
upplied by transfecting 9 mg of supercoiled tRNA-
lasmid into the packaging cells is at a level capable
d on Akv MLV with the PBS sequence highlighted. The wt pro PBS of
erfect or near-perfect match to tRNA acceptors for pro (PBS-B2), gln
PBS-Lys1.2(m)] or to a synthetic tRNAx2 (PBS-x2). Nucleotide mutations
, and PBS-Lys1.2(m) from PBS-Lys1.2 are shown in bold. The G418-
gions in the LTRs, which are reconstituted to wt sequence after reverse
imary sequence of a 109-bp subfragment of the endogenous murine
ucleotides mutated in the engineered tRNAB2 and tRNAx2 (Lund et al.,
cription are shown above the sequence. Nucleotides annealing to the
he figure. (C) Clover-leaf structure of the murine tRNAPro (after Harada
indicated.s base
s with p
ys1.2,
BS-Phe
inker re
les. Pr
enes. N
or transf competing with the endogenous tRNAs in comple-
entation of the vectors.
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371MLV EXPRESSION IN EC CELLS BY PRIMERS AND PBSsFIG. 2. Replication of vectors with a mismatched PBS-tRNA complement in fibroblasts and EC cells. Akv MLV-derived vectors containing wt pro PBS
PBS-Pro) or the single nucleotide-mutated B2 PBS (PBS-B2) were transfected into BOSC 23 transient packaging cells alone or in combination with
ynthetic minigenes encoding tRNAPro or tRNAB2, and viral supernatant was transferred in parallel to NIH/3T3 (left) and F9 EC cells (right). Virus
particles containing a B2-pro mismatch at the PBS region in the RNA genome result in both PBS-Pro and PBS-B2 proviruses in the target cells. After
G418 selection, neo-expressing proviruses in pools of resistant clones were analyzed by extension of an end-labeled primer (horizontal arrow) in the
presence of ddATP. Twenty-two-mer B2- and 24-mer pro-indicative bands, deriving from termination at the first T in a PBS-B2 and a PBS-Pro template,
respectively, were resolved by polyacrylamide gel electrophoresis, and the gel was exposed in a Personal Molecular Imager Fx and visualized by
using Quantity One. In permissive fibroblasts (left), both PBS-Pro and PBS-B2 are expressed, and tRNAB2 is used to assess participation of the
on-natural tRNA in reverse transcription. In F9 EC cells (right), the PBS-Pro vector is repressed and only PBS-B2 is present after selection for neo
xpression. Transduction titers of the particular PBS-tRNA combination and number of colonies used for primer extension are indicated below each
ane. Data are from experiments 5 and 7 (for PBS-Pro) of Table 1.
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372 MODIN ET AL.MLV expression in EC cells by use of artificial tRNAB2
In accordance with a silencer coinciding with the wt
pro PBS region, the vector PBS-Pro transduces F9 cells
poorly, with titers ranging from 1 to 2.6 3 101, whereas
BS-B2 containing the EC escape mutation (Barklis et al.,
986) evades silencing obtaining titers from 1.1 3 102 to
103, although F9 cells are still less transducable than
IH/3T3 fibroblasts (Table 1). We sought to avoid the
ilencing of PBS-Pro by complementation with a syn-
hetic tRNA molecule providing the B2 escape mutant.
ecause the absolute titer of different virus stocks is
ubject to experimental variation, the NIH/3T3-to-F9 ra-
io, the restriction index (Kempler et al., 1993), is used to
compare repression in EC cells of various constructs
within the same experiment. Based on this ratio, PBS-B2
is repressed at a level of only 1–4% compared with
PBS-Pro in repeated experiments. Transduction efficien-
cies obtained by PBS-B2 cotransfected with tRNAPro or
B2
T
Vector Transd
Vector 1 tRNA Experiment
Titer
F9b
PBS-Pro 1 1.6 3 101
4 2.6 3 101
6 5.0 3 100
7 5.0 3 100
8 1.0 3 100
9 1.0 3 100
PBS-B2 1 1.8 3 102
2 1.0 3 103
4 4.7 3 102
5 4.5 3 102
7 2.0 3 102
8 1.1 3 102
9 2.5 3 102
PBS-B2 1 tRNAPro 3 3.1 3 102
4 1.2 3 103
5 4.3 3 102
9 2.0 3 102
PBS-B2 1 tRNAB2 1 3.0 3 102
2 3.8 3 103
4 3.6 3 103
5 4.8 3 102
9 2.9 3 102
PBS-Pro 1 tRNAPro 3 1.3 3 101
4 8.6 3 101
9 1.0 3 100
PBS-Pro 1 tRNAB2 3 1.3 3 102
4 3.8 3 102
5 1.6 3 102
9 4.4 3 101
PBS-Gln 1 1.2 3 103
2 4.6 3 103
4 6.7 3 103tRNA do not differ significantly from the results with
BS-B2 alone, indicating no adverse effect of the syn-hetic tRNA (Table 1). Similarly, compared with PBS-Pro
lone, PBS-Pro 1 tRNAPro is repressed at 41%. However,
silencing can be evaded by complementing PBS-Pro with
synthetic tRNAB2, giving titers on F9 cells from 4.4 3 101
to 3.8 3 102 and restriction indices matching those for
BS-B2 (Table 1). A restriction index as high as 3437
btained with the PBS-Pro 1 tRNAB2 combination in one
xperiment might indicate that alleviation of repression
s not in all cases as efficient as with the PBS-B2 vector,
finding that can be explained by the simultaneous
resence of endogenous tRNAPro primers, which have to
be outcompeted.
The results from primer extension analysis on pools of
G418-resistant F9 clones confirm tRNAB2-mediated es-
ape of the PBS-Pro vector as demonstrated in titering
ssays. PBS-B2 alone or together with tRNAPro or tRNAB2
gives rise only to detectable levels of the 22-mer B2 band
(Fig. 2, right, lanes 7–9), indicating efficient silencing of
Efficienciesa
l) NIH/3T3
% PBS-Pro repressiondNIH/3T3c F9
5.0 3 105 31,250 100
4.6 3 105 17,690 100
1.8 3 105 36,000 100
1.0 3 105 20,000 100
5.5 3 103 5500 100
1.3 3 104 13,000 100
9.7 3 104 539 2
1.8 3 104 18 NA
3.7 3 105 787 4
4.9 3 105 1089 NA
4.0 3 104 200 1
1.7 3 104 154 3
2.2 3 104 88 1
3.3 3 105 1064 NA
5.6 3 105 467 3
5.1 3 105 1186 NA
1.9 3 105 950 8
1.1 3 105 367 1
1.7 3 104 4 NA
5.5 3 105 153 1
3.6 3 105 750 NA
5.9 3 104 203 2
5.0 3 105 38,461 NA
6.3 3 105 7325 41
9.5 3 103 9500 73
1.0 3 105 769 NA
1.6 3 105 421 2
5.5 3 105 3437 NA
1.3 3 104 295 2
3.9 3 105 325 1
1.5 3 105 33 NA
1.1 3 106 164 1ABLE 1
uction
(CFU/mrevertant pro PBS proviruses; the 24-mer pro band in
lane 6 derives from the few resistant colonies obtained
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373MLV EXPRESSION IN EC CELLS BY PRIMERS AND PBSsby PBS-Pro transduction, which were expanded for
primer extension analysis. However, PBS-Pro 1 tRNAB2
transduction of F9 cells results in the majority of provi-
ruses harboring a B2 PBS (Fig. 2, lane 10), demonstrating
utilization of the synthetic tRNA in competition with the
endogenous tRNAPro and establishing symmetry be-
tween a mutation in the PBS and in the reverse transcrip-
tion primer in conferring escape to EC repression. We do
not know the reason for the presence of the weaker
24-mer pro band seen with PBS-Pro 1 tRNAB2 (Fig. 2,
lane 10) and in some cases also with PBS-B2 1 tRNAPro
(data not shown). It is known that some sites of integra-
tion may confer expression of pro PBS-containing vec-
tors in EC cells (Barklis et al., 1986). Hence it is possible
hat stochastic variations in permissive integration sites,
ithin the limited number of clones present in the pools
nalyzed, may affect the intensity of the pro PBS band.
ompared with the distribution in unrestricted NIH/3T3
TABLE 1
Vector 1 tRNA Experiment
Titer
F9b
PBS-Lys3 1 2.0 3 102
2 5.3 3 102
4 4.1 3 102
PBS-Phe 8 7.0 3 101
8 7.0 3 101
PBS-Phe(m) 6 9.0 3 101
6 9.0 3 101
6 7.0 3 101
7 6.0 3 101
7 5.0 3 101
7 6.0 3 101
PBS-Lys1.2 8 1.0 3 100
8 3.0 3 100
9 3.0 3 100
9 2.0 3 100
PBS-Lys1.2(m) 6 6.0 3 100
6 8.0 3 100
6 5.0 3 100
7 1.0 3 101
7 7.0 3 100
7 0
9 1.2 3 101
PBS-x2 1 0
2 0
4 0
BS-x2 1 tRNAx2 1 3.0 3 102
2 1.0 3 103
3 1.3 3 103
4 2.5 3 103
a NIH/3T3 and F9 cells were transduced in parallel with dilutions of v
9 mg of tRNA plasmid or 1 mg of vector 1 9 mg pUC19 where no tRN
b F9 cells were seeded at 3 3 103 cells/cm2 in 6-wells dishes.
c NIH/3T3 cells were seeded in P10 dishes or in 6-well dishes (exp
d The NIH/3T3-to-F9 ratio was compared with the corresponding ratells, the order of appearance of increasing pro PBS
and intensities are essentially the same, i.e. PBS-B2 1tRNAB2 , PBS-B2 1 tRNAPro , PBS-Pro 1 tRNAB2, which
s why the distribution in F9 might simply reflect the
mount of tRNAB2 participating in reverse transcription,
shifting the transduced PBS toward the B2.
PBS determinants of MLV repression
To further characterize PBS silencer-mediated re-
pression, we studied the negative effect of different
PBS sequences when at their natural position, medi-
ating their functions in reverse transcription. A panel
of Akv MLV-derived vectors harboring a variety of PBS
sequences in place of the pro PBS with perfect or
near-perfect match to naturally occurring tRNAs (Fig.
1) were tested for transduction efficiencies. The intro-
duced PBS sequences complement tRNA acceptors
for glutamine (PBS-gln), lysine3 (PBS-Lys3), lysine1.2
(PBS-Lys1.2), and phenylalanine (PBS-Phe). PBS-
tinued
l) NIH/3T3
% PBS-Pro repressiondNIH/3T3c F9
7.8 3 104 390 1
1.5 3 104 28 NA
4.4 3 105 1073 6
2.3 3 103 33 1
8.6 3 103 123 2
1.5 3 104 167 1
1.5 3 104 167 1
1.8 3 104 257 1
9.0 3 103 150 1
9.0 3 103 180 1
1.0 3 104 167 1
1.4 3 103 1400 25
5.9 3 103 1967 36
6.4 3 103 2133 16
9.0 3 103 4500 35
1.0 3 104 1667 5
1.0 3 104 1250 4
8.5 3 103 1700 5
1.0 3 104 1000 5
5.0 3 103 714 4
5.0 3 103 NA NA
6.3 3 103 525 4
1.3 3 101 NA NA
3.0 3 100 NA NA
1.4 3 101 NA NA
9.9 3 104 330 1
1.0 3 104 10 NA
1.4 3 105 108 NA
2.8 3 105 112 1
ticles from BOSC 23 cells transiently transfected with 1 mg of vector 1
icated.
s 8 and 9) at 104 or 5 3 103 (experiment 9) cells/cm2.
BS-Pro within the same experiment. NA, not applicable.—Con
(CFU/m
irus par
A is indLys1.2(m) and PBS-Phe(m) each harbor a single base
substitution, C 3 T and G 3 T, respectively (Fig. 1),
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374 MODIN ET AL.giving a C-A and a G-A mismatch in the PBS after
second-strand transfer. Virus titration assays were
done on NIH/3T3 and F9 cells in parallel to allow a
comparison of different constructs within an experi-
ment.
In NIH/3T3 fibroblasts, all PBS mutations sustained
efficient vector replication in the presence of endoge-
nous or cotransfected synthetic tRNA primers, confirm-
ing the ability of Akv MLV-derived vectors to replicate by
use of various tRNA molecules (Lund et al., 1993, 1997,
000a). In general, for each construct, restriction indices
aried from one experiment to another, but they were
elatively consistent when comparing vectors within an
xperiment. Hence all vectors with functional PBS se-
uences, except PBS-Lys1.2, displayed restriction indi-
es paralleling those for PBS-B2 and were repressed at
–6% the level of PBS-Pro in F9 cells, indicative of relief
rom repression (Table 1). In particular, in parallel trans-
uctions, both PBS-Lys3 and PBS-Phe vectors behaved
imilarly to PBS-B2 in terms of restriction indices, as did
he single mismatch vector PBS-Phe(m) (Table 1). Con-
istent with this, no repression of PBS-Phe(m) in F9 was
bserved in primer extension analysis performed on
ools of G418-selected clones. Both NIH/3T3 and F9
BS-Phe(m)-transduced cells showed equal distribution
f 22-mer phe(m) and 33-mer phe PBS bands, indicative
f balanced reversion to wt phe PBS in permissive cells
f a PBS-tRNA complement with a single mismatch (Fig.
, lane 4 and lanes 8–9).
PBS point mutation escaping EC repression of
ys1.2 PBS
Of the transduced vectors with alternative PBS se-
uences, only PBS-Lys1.2 showed substantial repres-
ion in F9 cells, at approximately one third the level of
BS-Pro (Table 1). Interestingly, when we analyze PBS
equences in pools of selected clones from cells
ransduced with the mutant PBS-Lys1.2(m) by primer
xtension, PBS-Lys1.2(m) is demonstrated to escape
epression in F9 cells compared with the revertant
BS-Lys1.2 (Fig. 3). In NIH/3T3 cells, corresponding
evels of lys1.2(m) 22-mer and lys1.2 27-mer bands are
een, indicating no restriction (Fig. 3, lane 3). In F9
ells, however, in accordance with the restriction seen
n titer assays, the 27-mer lys1.2 provirus-derived band
s hardly visible, whereas PBS-Lys1.2(m) appears to
scape repression (Fig. 3, lane 7). A closer inspection
f transduction efficiencies, albeit generally low on
oth F9 and NIH/3T3 cells in experiments 6–9, reveals
tendency for PBS-Lys1.2(m) repression to be inter-
ediate to repression of PBS-Lys1.2 on the one hand
nd PBS-B2, PBS-Phe, and PBS-Phe(m) on the other,
onfirming escape of the lys1.2(m) PBS proviruses in
he population.
t
aEscape from EC repression by engineered PBS-tRNA
complement
The PBS-impaired vector PBS-x2 (Lund et al., 1997)
harbors nine nucleotide alterations in the PBS compared
with the vector PBS-Pro (Fig. 1A). The mutations were
chosen to give the least possible match to any known
murine tRNAs, yet conserved the 59 TGG matching the
CA tail of a tRNA molecule and the five most 39 nucle-
tides constituting a part of the intragenic B box pro-
oter element (Lund et al., 1997) (Fig. 1B). The replica-
FIG. 3. Primer extension analysis of PBS-tRNA mismatched vectors.
(A) Schematic representation of termination products resulting from
primer extension performed with the single nucleotide-mutated PBS-
B2, PBS-Lys1.2(m), and PBS-Phe(m) vectors and their respective PBS
revertant proviruses, PBS-Pro, PBS-Lys1.2, and PBS-Phe, as templates.
Extension of an end-labeled primer (horizontal arrow) was performed in
the presence of ddATP for PBS-B2-transduced cells or ddTTP for cells
transduced with PBS-Lys1.2(m) and PBS-Phe(m) vectors. (B) Primer
extension analysis of PBS-Pro-, PBS-B2-, PBS-Lys1.2(m)-, and PBS-
Phe(m)-expressing G418-resistant populations of NIH/3T3 (left) and F9
cells (right). Termination products were resolved by polyacrylamide gel
electrophoresis, and the gel was exposed in a Personal Molecular
Imager Fx and visualized by using Quantity One. The samples are from
experiment 7 of Table 1.ion capacity of PBS-x2 is severely reduced due to lack of
complementary tRNA primer but is restored to near-wt
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375MLV EXPRESSION IN EC CELLS BY PRIMERS AND PBSslevels by cotransfection of a matching synthetic mole-
cule tRNAx2 (Lund et al., 1997). To assess the possibility
of attaining further escape from PBS silencing than that
provided by B2 or alternative tRNA-matching PBSs,
PBS-x2 with the lowest homology to natural sequences
was tested in our transduction system.
A very low but reproducible number of G418-resistant
clones was obtained after transfer of PBS-x2 to fibro-
blasts (Table 1). Expressed proviruses from three indi-
vidual clones were PCR amplified using a primer set that
allowed specific amplification of proviruses derived from
replication of the input PBS-mutated vectors (Lund et al.,
1993). By both the size of the amplified fragment and
sequence analysis of transduced PBS and flanking se-
quences, exact identity to the input PBS-x2 vector was
demonstrated (data not shown), indicating that low inci-
dence reverse transcription of the vector might have
occurred by priming not involving tRNA-PBS-x2 perfect
complementarity (Mikkelsen et al., 1996, 1998). Cotrans-
fection of a matching synthetic tRNAx2 (Figs. 1B and 1C)
reestablished replication of PBS-x2 in NIH/3T3 cells to wt
levels as shown previously (Lund et al., 1997). In F9 cells,
PBS-x2 is efficiently impaired displaying no transduction
even after transfer of milliliter levels of viral supernatant
(Table 1). However, the ability of tRNAx2 to restore repli-
cation also applies to these cells, which are efficiently
transduced by the PBS-x2-tRNAx2 complement. Hence
elief from PBS silencer-mediated repression in F9 is
emonstrated both by inclusion, at the homologous po-
ition in the vectors, of alternative PBS sequences func-
ioning in reverse transcription via endogenous tRNA
rimers and by use of a synthetic PBS-tRNA comple-
ent. Notably, the synthetic PBS-tRNA complement pro-
ides no further relief from repression than that conferred
y the B2 mutation or by the PBS matching alternative
RNAs.
DISCUSSION
In this study, we analyzed PBS-tRNA interactions dur-
ng a single round of replication of MLV by replacement
ith alternative sequences in terms of (1) utilization of an
ngineered primer in competition with endogenous
RNAs and (2) repression effects of different PBS-tRNA
ets in EC cells.
The ability of MLV to replicate efficiently using various
aturally occurring PBS-tRNA primer complements has
een previously demonstrated (Lund et al., 1993) and
sed in the engineering of an artificial primer comple-
entation system (Lund et al., 1997). In that system, a
synthetic gene encoding a tRNA-like molecule is capable
of restoring replication of a complementary vector with a
mutationally impaired PBS to near-wt levels when
present in the packaging cells during transient produc-
tion of virus particles (Lund et al., 1997). In the work
presented here, we show that an engineered primer,without perfect match to the PBS, functions in reverse
transcription of an Akv MLV-derived vector PBS-Pro in
competition with endogenous tRNAs. As a genetic
marker for primer utilization, the single base pair PBS
mutant B2 was incorporated into the engineered tRNA.
Because both the primer and the PBS sequence are
copied during reverse transcription to generate the
transduced PBS (Gilboa et al., 1979), a mutation in either
of them is predicted to appear in approximately half of
the integrated proviruses (Barklis et al., 1986; Berwin and
Barklis, 1993). When we analyze proviruses of the NIH/
3T3 target population by primer extension dideoxy termi-
nation (Modin et al., 2000a,b), a PBS-Pro vector transfers
only proviruses with pro PBS, whereas PBS-B2 vectors
replicating via tRNAPro alone shows equal distribution of
ro and B2 PBS proviruses as predicted from reversion
o wt. Cotransfecting each vector with tRNAB2, however,
hifts these distributions toward a higher frequency of B2
BS proviruses, indicating that to some extent the engi-
eered tRNAB2 is used as primer during the transfer of
both PBS-Pro and PBS-B2 vectors (Fig. 2, left). Previously,
in vitro transcription and some degree of posttranscrip-
tional modification of the engineered tRNA have been
demonstrated (Lund et al., 2000b). The results presented
here indicate that the cis-elements contained in the con-
struct are sufficient to allow function of the engineered
primer even on a background of competing endogenous
tRNAs. Notably, the C-to-T substitution corresponding to
the B2 PBS mutation localizes to one of the intragenic
RNA polymerase III promoters of the engineered tRNA
gene (Fig. 1B), giving a single nucleotide deviation from
the published consensus sequence of the B box (Pavesi
et al., 1994), presumably without detrimental effects on
gene expression.
The efficient function of an engineered primer in re-
verse transcription was exploited to assess PBS primer
contributions to transcriptional silencing of MLV in undif-
ferentiated embryonic cells. By providing the PBS es-
cape mutant B2 (Barklis et al., 1986) in the tRNA primer,
we demonstrate symmetry of the PBS and the primer
during reverse transcription. A PBS-Pro vector that is
efficiently silenced in the EC cell line F9 is thus relieved
from repression by the engineered tRNAB2 cotransfected
into the packaging cells as measured by transduction
efficiencies and confirmed in primer extension analysis
showing the appearance of B2 PBS proviruses. From the
results for both fibroblasts and EC cells, we conclude
that cellular repair mechanisms presumably correcting
mismatches in the PBS of the provirus do not distinguish
between sequences derived from the PBS or the primer.
For each PBS-primer combination, restriction indices var-
ied from one experiment to another, but fluctuations were
relatively consistent when comparing constructs within
an experiment.The results obtained from transduction of Akv MLV-
derived vectors with substitution of the natural pro PBS
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376 MODIN ET AL.show that all except one of the alternative PBS se-
quences escape PBS silencer-mediated repression in F9
cells. Primer binding sites matching tRNAs gln, lys3, and
phe and the engineered tRNAx2 are all compatible with
expression in F9 cells at levels comparable to what is
accomplished by PBS-B2 containing the original PBS
escape mutant B2 identified by Barklis et al. (1986).
Previously, PBS sequences complementary to tRNAGln
(Grez et al., 1990; Petersen et al., 1991) and tRNALys3
(Yamauchi et al., 1995) have been reported to mediate
eplication of MoMLV-derived vectors in undifferentiated
ells, whereas contributions from other alternative PBS
equences to repression were assessed from a position
ownstream of a gln PBS responsible for replication of
he vectors (Yamauchi et al., 1995). This design sepa-
ated the repressor function of the test fragments from
heir PBS functions, yet concomitantly introduced two
BS sequences into the same vector, as opposed to one
BS present in the natural context. Under those condi-
ions, PBS sequences for isoleucine, methionine, and
ryptophan exhibited no silencing activity, and those for
he and lys3 exerted low but variable repression, reduc-
ng viral infectivities 2- to 10-fold compared with a B2
BS, whereas a PBS matching tRNALys1.2 exerted repres-
ion at 29–120% the level of a wt pro sequence (Yamau-
hi et al., 1995). These results thus pointed to the exis-
ence of gradual levels of repression mediated by differ-
nt PBS sequences. In the context of the Akv MLV-based
ectors used here, we see no evidence of negative
ffects exerted by PBS-Phe or PBS-Lys3 in particular.
he transduction data rather reflect a drawback inherent
o titering assays, namely, variations in transfer efficien-
ies derived from variable transfection of producer cells,
ell density, time of virus harvest, growth conditions, and
o on (Weiher et al., 1987). As demonstrated by our
epeated experiments, these differences are only to a
ertain extent evened out by comparing restriction indi-
es rather than absolute titers. Thus subtle differences
etween vectors based on titering assays alone may be
nterpreted with caution. For PBS-Lys3, PBS-Phe, and the
ingle mismatch vector PBS-Phe(m), although restriction
ndices vary and reach 103 for PBS-Lys3 in one case, they
are in general comparable to those for PBS-B2 within the
same experiment. In support of this, we analyzed provi-
ruses of PBS-Phe(m)-transduced cells by primer exten-
sion dideoxy termination and found balanced reversion
to phe PBS in both NIH/3T3 and F9, indicating no dis-
crimination between these two phe PBS sequences. We
cannot exclude, however, that derepression could have
been obtained by the choice of another point mutation in
the phe PBS. Hence from the data in Table 1, it appears
that all vectors with substitutions of the wt PBS except
PBS-Lys1.2 escape repression to similar extents. In a
study fine-mapping the inhibitory activity of the PBS re-
gion via DNA transfections, expression from a recombi-
nant harboring the B2 PBS was identical to that from anunrestricted control lacking the entire PBS (Loh et al.,
1990). Our results, directly comparing transfer efficien-
cies of various primer binding sites, determine that the
single G-to-A mutation of B2 PBS is a complete escape
from PBS silencer-mediated repression. PBS-Gln har-
bors the identical mutation in addition to four others
distinguishing it from PBS-Pro yet do not differ from
PBS-B2 in terms of relief from repression. Importantly, the
synthetic PBS designed to have the least possible match
to any known tRNA does not, when complemented by an
engineered tRNAx2 during replication, give further allevi-
ation than that provided by the B2 and natural tRNA-
matching PBSs. The data hence do not support a model
of general repression by tRNA-matching sequences.
Among the alternative PBS sequences tested here,
only lys1.2 inhibits transcription substantially in EC cells,
in accordance with earlier observations by Yamauchi et
al. (1995), who found the titer of a gln PBS vector to be
reduced more than 30-fold by a downstream positioned
lys1.2 PBS relative to a B2 PBS. Our vector PBS-Lys1.2
displays transduction titers of #3 on F9, giving restriction
indices at least 10-fold above those for PBS-B2 in parallel
experiments. A variant vector PBS-Lys1.2(m) containing a
single nucleotide mutation displayed corresponding
transduction efficiencies. However, a closer comparison
of repression levels indicates that although PBS-Lys1.2 is
inhibited approximately 3 times less than PBS-Pro, PBS-
Lys1.2(m) repression appears to be intermediate to that
exerted by PBS-Lys1.2 on the one hand and the vectors
PBS-B2, PBS-Phe, and PBS-Phe(m) on the other in par-
allel transductions. This was substantiated by primer
extension analysis performed on PBS-Lys1.2(m)-trans-
duced populations, where in permissive fibroblasts, the
mutated vector showed balanced reversion to wt lys1.2
PBS, whereas in F9, only low levels of lys1.2 PBS rever-
tants could be detected. Transcriptional inhibition medi-
ated by the PBS region has been correlated to in vitro
binding of a putative EC repressor, factor A, to a wt pro
but not to a mutated B2 probe spanning the PBS region
(Loh et al., 1990; Petersen et al., 1991; Yamauchi et al.,
1995). In addition, Yamauchi et al. (1995) tested binding to
alternative PBS sequences and observed a complex with
a mobility similar to that of factor A with a lys1.2 PBS
probe, but because the two factors did not cross-com-
pete for binding, they were suggested to be distinct
factors (Yamauchi et al., 1995). Our results lend further
support to the existence of a negative element coinciding
with the lys1.2 sequence and show that a single C-to-T
mutation at the eighth position of the PBS partially re-
lieves inhibition, a finding comparable to the G-to-A es-
cape mutation in B2 PBS. However, PBS-B2 is still supe-
rior to PBS-Lys1.2(m) in conferring escape from repres-
sion, probably reflecting that it was selected because of
its expression capacity in EC cells as opposed to the
arbitrarily designed mutation in PBS-Lys1.2(m).
In conclusion, we find alleviation of pro PBS silencer-
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377MLV EXPRESSION IN EC CELLS BY PRIMERS AND PBSsmediated repression by the B2 PBS escape mutation
provided in an engineered tRNA molecule or by ex-
change of the wt PBS with natural or synthetic tRNA-PBS
sets. No further relief than that obtained with a B2 PBS or
alternative tRNA-matching PBSs is achieved by the syn-
thetic tRNA-PBS complement. In addition, we confirm
that the lys1.2 PBS of visna, spuma, and Mason-Pfizer
monkey viruses is also subject to transcriptional con-
straints in the context of a MLV vector and find a single
point mutation in lys1.2 PBS to partially relieve the re-
pression.
MATERIALS AND METHODS
PCR mutagenesis and cloning procedures
All vectors, inclusive PBS sequence, and tRNA-like
primers are shown in Fig. 1. The vectors are contained in
a pUC19 plasmid backbone and consist of truncated
LTRs of Akv MLV (Van Beveren et al., 1985) flanking 258
bp of the 59 UTR with PBS sequence, a Tn5 fragment
encompassing the neomycin phosphotransferase en-
coding gene (neo) (Beck et al., 1982), and 407 nt includ-
ng part of Akv MLV env and 39 UTR. Construction of the
lasmid vectors pPBS-Pro, pPBS-Gln1, pPBS-Lys3 (Lund
t al., 1993), pPBS-x2 (Lund et al., 1997), and pPBS-
he(m) (pPBS-BRN11ma in Lund et al., 2000a) by PCR-
ediated site-directed mutagenesis has been described
reviously. Briefly, the 59 part of the vectors was amplified
rom the transmission vector ptvAkvneo (Paludan et al.,
989), generating a 618-bp fragment carrying the modi-
ied PBS sequence, which was connected by PCR-aided
verlap extension to the likewise PCR-amplified 39
734-bp portion of the vectors. During amplification, the
TRs were truncated by the introduction of specific re-
triction sites into the 59 U3- and the 39 U5 region for
ubsequent cloning into pUC19 (Lund et al., 1993).
PBS-B2 was generated by a similar procedure using
rimer 2 (59-CCTGGGCGGGGGTCTCCAAATCTCGGAC-
AGCCCCCAAAT-39, single nucleotide C-to-T mutation
n bold) introducing the B2 PBS (Barklis et al., 1986). For
he construction of pPBS-Phe, pPBS-Lys1.2, and pPBS-
ys1.2(m), the PBS of pPBS-Pro was replaced by cloning
f a 735-bp EcoRI–SpeI fragment amplified from ptvAkv-
eo using the previously described EcoRI-linker LTR
rimer 1 (59-GGGAATTCTACCTTACGTTTCCCCGACCAG-
GCTGATGTTCTCAG-39) (Lund et al., 1993) and a 180-nt-
ong oligodeoxynucleotide 3 (PBS sequence underlined)
59-GGACTAGTACAGAATCAGACGCAGGCGCAAAA-
GTAGATGCCGGCACACACACACACACGCACAAAGAC-
GAGACGGAGACAAAACGATCGCTGGCCAGCTTACCT-
CCGACGGTGGGTCGGTGGTCCCTGGGCGGGGGTCTC-
AATCCCGGGTTTCGGCACCAAATGAAAGACCCCCAG-39)
introducing Phe PBS, 4 (59-GGACTAGTACAGAATC-
AGACGCAGGCGCAAAAAGTAGATGCCGGCACACACACA-
CACACGCACAAAGACAGAGACGGAGACAAAACGATCG-
CTGGCCAGCTTACCTCCCGACGGTGGGTCGGTGGTCCC-TGGGCGGGGGTCTCCAAGCCCCACGTTGGGCGCCAAA-
TGAAAGACCCCCAG-39) introducing lys1.2 PBS, or 5
(59-GGACTAGTACAGAATCAGACGCAGGCGCAAAAA-
GTAGATGCCGGCACACACACACACACGCACAAAGACA-
GAGACGGAGACAAAACGATCGCTGGCCAGCTTACCTCC-
CGACGGTGGGTCGGTGGTCCCTGGGCGGGGGTCTCCA-
AGCCCCACGTTAGGCGCCAAATGAAAGACCCCCAG-39)
introducing lys1.2(m) PBS with a point mutation, with each
encompassing the SpeI site in the 59 UTR. PCR amplifica-
tion was performed in 100 ml of PCR buffer containing 100
ng ptvAkvneo template, 25 pmol of each primer, 0.2 mM
dNTPs, 2.5 U of AmpliTaq DNA polymerase (Perkin–Elmer),
and 1 U of Pfu polymerase (Stratagene, La Jolla, CA) in 12
cycles (1.2 min at 94°C, 1.2 min at 60°C, and 2.5 min at
73°C). All PCR-amplified sequences were verified by se-
quencing. The plasmid ptRNAB2 encoding the putative
tRNAB2 molecule was constructed essentially as described
reviously for tRNAx2 (Lund et al., 1997) (therein designated
pRNAx2). Briefly, a 23-base elongation primer 6 (59-
AGGGAATTCTCGAGCTCAAGCTTATAAAAACTTGGG-
TC-39) was annealed to a 127-base oligodeoxynucleotide
(59-CCGGAATTCGAAAACGAAGAAACAAAGTTTACA-
TCTGGCTCGTTGGTCTAGGGGTATGATTCTCGCTTAGGGT-
GCGAGAGGTCCCGGGTTCAAATCTCGGACGAGCCCAAG-
TTTTTATAAGCTTTCC-39, single nucleotide C-to-T mutation
in bold) containing the RNA cassette and recognition sites
for EcoRI and HindIII (underlined), extended with Seque-
nase version 2.0 (Amersham Pharmacia Biotech) (Modin et
al., 2000), and cloned into pPUR (Clontech, Inc.) via EcoRI–
HindIII digestion. ptRNAPro encodes 446 bp of the putative
tRNAPro molecule obtained by PCR amplification of the
urine Pro-tRNA gene (Russo et al., 1986) using primers 8
(59-CCGCTGCAGGTACCGTTGTCAATCATTAAATTTTGAA-
CCT-39) and 9 (59-CCGGAATTCTCGAGAATTGGCCTTTTG-
GCTTGCG-39) and cloned into pBluescript (Stratagene) via
PstI and EcoRI (underlined) digestion. All oligodeoxynucle-
otides were purchased from DNA Technology A/S (Aarhus,
Denmark).
Cell cultures, transfection, and transduction
The human kidney-derived BOSC 23 packaging cell
line (Pear et al., 1993) was passaged three or four times
in HAT-Dulbecco’s modified Eagle’s medium (DMEM)
selective medium (Pear et al., 1993) to ensure expression
of the env gene. Subsequent maintenance was in DMEM
supplemented with 10% fetal calf serum (FCS) (Gibco
BRL; Life Technologies). The mouse embryonic carci-
noma (EC) cell line F9 (Strickland, 1981; Bernstine et al.,
1983) was grown on 0.1% gelatin-coated culture flasks in
DMEM supplemented with 10% FCS. NIH/3T3 mouse
fibroblasts were grown in DMEM with 10% NCS. All cell
culture media contained 100 U/ml penicillin and 100
mg/ml streptomycin. For transduction of target cells,
4 2BOSC 23, seeded at 7 3 10 cells/cm on the day before
transfection, were transfected by the calcium phosphate
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378 MODIN ET AL.method (Graham and van der Eb, 1973) without a glycerol
shock with 1 mg of plasmid vector and either 9 mg of
lasmid encoding synthetic tRNA or 9 mg of carrier
UC19. Medium was renewed after 12–16 h, and virus
upernatant was harvested 48–72 h posttransfection,
iltered through a sterile 0.45-mm filter, and transferred
erially diluted to F9 and NIH/3T3 target cells [seeded at
F9) 3 3 103 and (NIH/3T3) 104 cells/cm2 on the day
efore transduction] in the presence of 5 and 6 mg/ml
Polybrene (Aldrich Chemical Co. Inc.), respectively. G418-
containing (Sigma, St. Louis, MO) selective media were
added 24 h posttransduction at (active compound) 600
mg/ml for fibroblasts and at 400 mg/ml for F9 cells, and
resistant colonies were counted after 10–14 days of se-
lection.
DNA preparation and primer extension analysis
For primer extension analysis of transduced vector
proviruses in NIH/3T3 and F9 cells, 59–170 G418-resis-
tant colonies were lysed with DNAzol in the culture
dishes, and genomic DNA was isolated according to
instructions provided by the manufacturer (Molecular
Research Center, Inc., Cincinnati, OH); for PBS-Pro and
PBS-Lys1.2(m), 10 and 33 G418-resistant colonies, re-
spectively, were pooled and expanded before DNA iso-
lation. Specific PCR amplification of integrated vector
proviruses was achieved using primer 10 (59-TTCATAAG-
GCTTAGCCAGCTAACTGCAG-39) matching Akv MLV po-
sition 7838–7865, which is reconstituted in the 59 LTR
after transduction of the vectors, and a neo-specific
primer 11 (59-XGGCGCCCCTGCGCTGACAGCCGGAA-
CAC-39, with X denoting biotin). PCR amplification, per-
formed on 1 mg of DNA template in a standard reaction
uffer with 2.5 U of AmpliTaq Gold (Perkin–Elmer Cetus),
as for 10 min at 95°C to activate the enzyme, followed
y 1 min at 94°C, 1 min at 60°C, and 3 min at 73°C in 40
ycles. Then 70 ml of PCR amplified product was purified
with Dynabeads (Dynal M-280) and denatured in NaOH,
and the biotinylated strand was used in primer extension
analysis with modified T7 DNA polymerase (Sequenase
version 2.0, Amersham Pharmacia Biotech) essentially
as described (Modin et al., 2000a). Briefly, an 18-mer
extension primer 12 (59-TTTCATTTGGGGGCTCGT-39) for
PBS-Pro and PBS-B2, 13-mer (59-GGGGGTCTTTCATTT-
GGT-39) for PBS-Phe, and 14-mer (59-GGGGGTCTT-
TCATTTGGC-39) for PBS-Lys1.2 was 59 labeled using
[g-32P]dATP and T4 polynucleotide kinase and annealed
o the respective template in 10 ml of the reaction buffer
upplied with the Sequenase enzyme by heating to 65°C
or 2 min and slowly cooling to room temperature. Ex-
ension was carried out for 10 min at 37°C after the
ddition of 5 ml of extension mix containing 3.25 U of
odified T7 DNA polymerase and for PBS-Pro and PBS-
2, 1 mM ddATP and 0.1 mM concentration each of dCTP,
GTP, and dTTP, and for PBS-Phe and PBS-Lys1.2(m), 1M ddTTP and 0.1 mM concentration each of dCTP,
GTP, and dATP. Reactions were terminated by the ad-
ition of 10 ml of formamide loading buffer (80% form-
amide, 1 mM EDTA, 0.1% xylene cyanol FF, 0.1% brom-
phenol blue in 13 TBE buffer) and heated to 95°C for 2
min, and the samples were analyzed on 20% polyacryl-
amide gels and exposed in a Personal Molecular Imager
Fx.
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